drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous genetically modified T cells expressing a chimeric antigen receptor targeting mesothelin; upon binding tumor mesothelin, the CAR activates T-cell signaling, cytokine release, and perforin/granzyme-mediated cytotoxicity.
nci_thesaurus_concept_id
C201275
nci_thesaurus_definition
Any preparation of chimeric antigen receptor (CAR)-expressing T-lymphocytes that targets the tumor-associated antigen (TAA) mesothelin (MSLN).
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells engineered to express a chimeric antigen receptor that binds mesothelin on tumor cells. Antigen engagement triggers CD3ΞΆ and costimulatory signaling (e.g., CD28/4-1BB), driving T-cell activation, proliferation, cytokine release, and perforin/granzyme-mediated cytotoxic killing of mesothelin-positive cells.
drug_name
Anti-mesothelin CAR-T cells
nct_id_drug_ref
NCT07010523